KB-1081

LY3361237-hIgG4-S228P

33655

Home » LY3361237-hIgG4-S228P

Background of LY3361237-hIgG4-S228P

B and T lymphocyte attenuator (BTLA) is an attractive target for a new class of therapeutics that attempt to rebalance the immune system by agonizing checkpoint inhibitory receptors (CIRs). LY3361237 is the first antibody drug that’s known to increase the activity of BTLA to inhibit the immune system, which means it has extraordinary potential as a therapy for autoimmune diseases.

Specifications

Catalog Number	KB-1081
Antibody Name	LY3361237-hIgG4-S228P
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P/F234A/L235A
Target	BTLA
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus.
Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA.

Use License Agreement

Research Use Only.

Not for use in diagnostic procedures or therapeutic applications.